Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 10/20 | 0.38 |
| ▸ | SYK | P43405 | 6/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1891304 | 0.94 | JAK3 (0.40) | JAK3SYKCYP2D6JAK2JAK1 | |
| SCHEMBL1893368 | 0.91 | JAK3 (0.38) | JAK3SYKCYP2D6JAK2JAK1 | |
| SCHEMBL1891154 | 0.91 | NPC1 (0.43) | NPC1ALDH1A1RAB9AJAK3SYK | |
| SCHEMBL1891272 | 0.91 | JAK3 (0.40) | JAK3SYKJAK2JAK1 | |
| SCHEMBL3433507 | 0.89 | KDM4E (0.39) | KDM4ENPC1ALDH1A1RAB9AJAK3 | |
| SCHEMBL1889855 | 0.88 | SYK (0.37) | JAK3SYKCYP2D6JAK2JAK1 | |
| SCHEMBL1888983 | 0.88 | SYK (0.36) | JAK3SYKCYP2D6JAK2JAK1 | |
| SCHEMBL1890867 | 0.88 | JAK3 (0.38) | JAK3JAK2JAK1 | |
| SCHEMBL1895443 | 0.87 | JAK3 (0.37) | JAK3JAK2JAK1 | |
| SCHEMBL2345189 | 0.85 | SYK (0.37) | KDM4EALDH1A1JAK3SYKCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247592-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | claimed |
| US-7939531-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-05-10 | — | — | US | claimed |
| EP-2247592-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | claimed |
| WO-2009106442-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | claimed |
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | claimed |
| EP-2247592-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-7939531-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939531-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-05-10 | — | — | US | disclosed |
| EP-2247592-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106442-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK2 | KDM4E 598/4885NPC1 4824/4885ALDH1A1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.